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Background: The aim of this study was to evaluate the effects of β-glucan on the expression of inflammatory
mediators and metabolomic profile of oral cells [keratinocytes (OBA-9) and fibroblasts (HGF-1) in a dual-chamber
model] infected by Aggregatibacter actinomycetemcomitans. The periodontopathogen was applied and allowed to
cross the top layer of cells (OBA-9) to reach the bottom layer of cells (HGF-1) and induce the synthesis of immune
factors and cytokines in the host cells. β-glucan (10 μg/mL or 20 μg/mL) were added, and the transcriptional factors
and metabolites produced were quantified in the remaining cell layers and supernatant.
Results: The relative expression of interleukin (IL)-1-α and IL-18 genes in HGF-1 decreased with 10 μg/mL or 20 μg/mL
of β-glucan, where as the expression of PTGS-2 decreased only with 10 μg/mL. The expression of IL-1-α increased with
20 μg/mL and that of IL-18 increased with 10 μg/mL in OBA-9; the expression of BCL 2, EP 300, and PTGS-2 decreased
with the higher dose of β-glucan. The production of the metabolite 4-aminobutyric acid presented lower
concentrations under 20 μg/mL, whereas the concentrations of 2-deoxytetronic acid NIST and oxalic acid decreased at
both concentrations used. Acetophenone, benzoic acid, and pinitol presented reduced concentrations only when
treated with 10 μg/mL of β-glucan.
Conclusions: Treatment with β-glucans positively modulated the immune response and production of metabolites.
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ImmunomodulationBackground
β-glucans from yeast have been used extensively as pro-
tective substances against infections with potent effects on
the innate and adaptive immune responses. β-glucans are
non-starch polysaccharides that make up structural cells
of plants and microorganisms [1]. The cell wall of Saccha-
romyces cerevisiae is an important source of β-glucans and
these represents about 50–60% of yeast [2]. The protective
effect of these compounds has been demonstrated in* Correspondence: muratar16@ecu.edu
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that these substances modulate allergy symptoms [4] and
have anticancer properties [5, 6]. Many hypotheses have
been put forward to explain the effects of β-glucans. Such
compounds can act by inhibiting the adhesion of patho-
gens to epithelial tissues of the digestive tract by blocking
carbohydrate-binding adhesins on bacteria; they stimulate
the immunocompetent cells in Peyer’s patches and the
consecutive activation of mechanisms of innate and adap-
tive immune defense; further, by adsorption of mycotoxins
in food (when linked to the diet) β-glucans inhibit their
toxic activity [2].
However, its effects on periodontal inflammation are
still poorly studied. Periodontal disease is a highly preva-
lent disease in the adult population. It is characterizedle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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odontal tissues in response to specific microorganisms
present in oral biofilm [7–10]. The pathogens associated
with periodontal disease are frequently present in the hu-
man subgingival microbiota and are represented mainly
by anaerobic gram-negative bacteria [11]. A. actinomyce-
temcomitans, Pasteurellaceae family, is a coccobacillus,
fermentative, gram-negative, capnophilic, non-motile, and
non-sporulating microorganism. This bacterium is consid-
ered the main etiological agent of localized aggressive
periodontitis lesions, but is also associated with chronic
periodontitis [12–18]. The progression of periodontal dis-
ease is associated with the virulence of the microorganism,
together with the susceptibility of the host [19]. There are
several virulence factors of A. actinomycetemcomitans that
collaborate for its pathogenicity in periodontitis [20].
Leukotoxin, cytolethal distending toxins, bacteriocins,
adhesins and lipopolysaccharide correspond to the variety
of the microorganism virulence factors that may be associ-
ated with the pathogenesis of localized aggressive
periodontitis [21]. These virulence factors attributed to A.
actinomycetemcomitans are responsible for interacting
with the host cells triggering an inflammatory response in
the tissues supporting the teeth [22].
Fibroblasts and epithelial cells are the first cells to be
activated in the oral cavity in response to exotoxic and
endotoxic virulence factors of A. actinomycetemcomi-
tans, performing an essential role in the production of
cytokines involved in the inflammatory process. After
this first local colonization, leukocytes (mainly mono-
cytes and neutrophils) and dendritic cells are recruited
to the site of infection giving sequence on inflammatory
response [22, 23].
Recently, in vivo studies have demonstrated that
β-glucans from S. cerevisiae present regulatory activity
toward metabolism [24] and also modulate the expres-
sion of cycloxygenase-2 (COX-2), receptor activator of
nuclear factor kappa-B ligand (RANK-L), and osteopro-
tegerin (OPG), decreasing alveolar bone loss caused by
induced periodontal disease (ligature) in normal and
diabetic animals [25]. However, knowledge of the
molecular and biochemical mechanisms involved in
β-glucan activity in periodontal disease is still not under-
stood, demanding further research with advanced tissue
culture techniques, examining the microbiota-host inter-
action. In that sense, the dual chamber model is an
interesting in vitro model that mimics the human peri-
odontum. It is constructed using a monolayer of epithe-
lial keratinocytes and a subepithelial layer of fibroblasts
on which the invasive periodontopathogen can be
applied [26].
Thus, this study aims to evaluate the effects of β-glucan
on the expression of inflammatory mediators and the
metabolomic profile of oral cells using a dual-chambermodel of epithelial and subepithelial cells infected by A.
actinomycetemcomitans.
Methods
Bacterial strain and cells
A. actinomycetemcomitans strain (D7S-1) [27], human
gingival epithelial cells (keratinocyte OBA-9) [28, 29]
and human gingival fibroblast - HGF-1(ATCC® CRL-
2014) were used in the present study.
β-Glucan
The β-glucan utilized was the glucan from baker’s yeast
S. cerevisiae (Sigma-Aldrich; St. Louis, MO), with a pur-
ity of 98%. Sterilized deionized water was used as the ve-
hicle for β-glucan dilution.
Antimicrobial activity
As a preliminary step, the antimicrobial activity and cyto-
toxicity of β-glucan were tested in order to determine the
subsequent doses in the dual-chamber model. Antimicro-
bial activity was evaluated in A. actinomicetemcomitans
after 24 h of treatment. Microorganisms were inoculated
(1 × 106 cfu/mL – colony-forming units per milliliter) in a
96-well microtiter plate with Trypticase Soy Broth (TSB;
Becton Dickinson, Franklin Lakes, NJ) and β-glucan was
immediately added in various concentrations (0 as control,
and then subsequently from 1 μg/mL to 100 μg/mL) to
determine the minimum inhibitory concentration (MIC)
[30]. Microplates were maintained in a humidified incuba-
tor at 37 °C and 5% CO2. Microplates were maintained in
a humidified incubator at 37 °C and 5% CO2. After 24 h,
the contents of the wells were inoculated in Petri dishes
with Trypticase Soy Agar (TSA; Becton Dickinson,
Franklin Lakes, NJ) and incubated for 3 days. After this
period, the cfu/mL was determined.
Cytotoxicity assay
The in vitro cytotoxic effect was measured by the fluoro-
metric resazurin method [31]. OBA-9 or HGF-1cells,
cultured in DMEN medium (Lonza,Walkersville, MD)
with10% of Fetal Bovine Serum - FBS (Lonza, Walkers-
ville, MD), were seeded (1 × 105 cells/mL) in a 96-well
microtiter plate and maintained in a humidified incuba-
tor at 37 °C and 5% CO2. After 24 h, cell morphology
was observed under an inverted microscope (EVOS FL;
Life Technologies, Carlbad, CA) to confirm their adher-
ence to the wells and to note their morphological
changes. β-glucan (1–100 μg/mL) was added to the cell
culture and incubated at 37 °C and 5% CO2. After 24 h,
the medium was discarded, cells were washed with warm
PBS (Lonza, Walkersville, MD), and replenished with
fresh medium containing resazurin (Cell Titer Blue
Viability Assay; Promega Corp, Madison, WI) [32]. Sub-
sequently the plate was incubated at 37 °C and 5% CO2.
Table 1 Treatment groups - experimental design
Groups Treatment
Control Model with aAa inoculated and no treatment
BG 10 Model with Aa inoculated and treated with 10 μg/mL of
β-glucan
BG 20 Model with Aa inoculated and treated with 20 μg/mL of
β-glucan
aAa Aggregatibacter actinomicetemcomitans
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new microplate and the fluorescence was read in a
microplate reader (SpectraMaxM5; Molecular Devices
Sunnyvale, CA) with excitation at 550 nm, emission at
585 nm, and a cut off of 570 nm.
Dual-chamber assay
The immunological effects of β-glucan were investigated
using a dual-chamber model to mimic the periodontum
(Fig. 1). Transwell inserts (8 μm pore × 0.3 cm2 of
culture surface; Greiner Bio-One, Monroe, NC) were sit-
uated in a 24-well plate and OBA-9 cells (1 × 105) were
seeded intranswell inserts. HGF-1cells (1 × 105) were
seeded in the basal chamber. The plates were incubated
at 37 °C in humid air containing 5% CO2 for 24 h. The
trans-epithelial electric resistance (TEER) of each cell
layer was measured with a Millicell-ERS volt-ohm meter
(Millipore, Bedford, MA). Cell layer confluence in the
Transwell insert was measured daily until optimal TEER
was reached (>150 Ohm/cm2) which was found on the
second day, when the medium in the basal chamber and
insert were replaced with new medium (DMEN) con-
taining A. actinomicetemcomitans (1 × 106 cfu/mL).
Medium containing the microorganism was added to
the insert, passing through the upper layer of cells
(OBA-9) and reaching the bottom cell layer (HGF-1)
[26]. Immediately after inoculation of the dual-chamber
with A. actinomicetemcomitans the β-glucan treatments
(10 μg/mL or 20 μg/mL) were added and the plate was
incubated at 37 °C in humid air containing 5% CO2. The
time of exposure of the microorganism to β-glucan was
24 h. Each experiment was repeated three times with
two replicates per group (n = 6) and the experimental
groups were divided as described in Table 1. The two
doses used were determined from the results found in
the antimicrobial activity and cytotoxicity assay.
Sample collection for analysis
After the treatment period, the liquid contents of the
wells were collected and centrifuged at 1200 rpm for
10 min. Following centrifugation, the supernatant wasFig. 1 Dual-chamber model containing OBA-9 cell (keratinocytes) in the to
inoculated with A. actinomicetemcomitans and treated with different dosesstored at −80 °C for subsequent metabolomic analysis.
The remaining cell layer on the surface of the inserts
and of the plate wells were used for RNA isolation
(OBA-9 and HGF-1 separately) for gene analysis in
quantitative real-timePCR.
Gene expression –quantitative real-time PCR
Total RNA was isolated according to the Qiagen RNea-
syMini Kit Protocol (Qiagen; Valencia CA). Purity and
quantity of RNA were measured in a NanoPhotometer
P360 (Implen; Westlake Village). Total RNA was con-
verted into single-stranded cDNA using a high-capacity
reverse transcription kit (QuantiTect Reverse Transcrip-
tion Kit; Qiagen; Valencia, CA). From the cDNA
obtained, an array for evaluation of gene expression of
inflammatory response by quantitative real-time PCR
(Prime PCR Pathway Plate/Acute Inflammation
Response; Bio-Rad, Hercules, CA), was performed. Based
on the results of the array, five genes/primers were
selected for detailed study: IL-1-α, IL-18, B-cell
lymphoma-2 (BCL-2), E1A Binding Protein (EP300) and
prostaglandin-endoperoxidesynthase-2 (PTGS-2) (Quan-
tiTect Primer Assay - Qiagen; Valencia, CA). For the se-
lected primers, QuantiTect SYBR Green PCR Kits
(Qiagen;Valencia, CA) were used. The reaction product
was quantified by relative quantification using GAPDH
as a reference gene. Data from standard threshold cycle
(TC) of the equipment in real time (CFX Connect-Bio-
Rad; Hercules, CA) were calculated and interpreted
using the scan tool data qPCR array. Analysis of the
relative quantitation was done using the ΔΔCt compara-
tive method [33].p layer (transwell insert) and HGF-1 cell (fibroblasts) in the bottom layer
of β-glucan
Fig. 2 Cytotoxicity assay of cells treated with different doses of
β-glucan: (a) OBA-9 cell (keratinocytes); (b) HGF-1 cell (fibroblasts).
Cell viability was presented in percentage (%). n = 6
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The cell culture supernatant contents of the wells were
collected and centrifuged at 1200 rpm for 10 min, at
room temperature. Then, the supernatant was properly
stored and sent for analysis at West Coast Metabolomics
Center (UC Davis Genome Center; Davis, CA) for subse-
quent metabolomic analysis.
The metabolites were separated by gas chromatog-
raphy/mass spectrometry (Agilent 6890, Santa Clara,
CA/Leco Pegasus IV, St. Joseph, MI) according to stand-
ard methodology. The metabolites found were submitted
to a comparison software and compared with a standard
library of metabolites. Subsequently the data were sub-
mitted to statistical analysis (West Coast Metabolomics
Centre (UC Davis Genome Center; Davis, CA) [34].
Statistical analysis
Statistical analyses were done using analysis of variance
(ANOVA). When F values indicated significant interac-
tions, these were unfolded between factors. The analyses
were performed in the statistical program SISVAR [35]
at a significance level of α = 0.05.
Results
The antibacterial activity of β-glucan started at 10 μg/
mL. Cytotoxicity assays were conducted in HGF-1 and
OBA-9 cells and the results are shown in Fig. 2. The first
concentration used was 10 μg/mL of β-glucan and re-
sulted in 125% viability for HGF-1 and 104% for OBA-9
cells (Fig. 2a). The second concentration used was
20 μg/mL of β-glucan and resulted in 100% viability for
HGF-1 and 90% for OBA-9 cells (Fig. 2b).
Quantitative real-time PCR results are presented in
Figs. 3 and 4. Based on gene expression results of the
inflammatory profile (acute inflammation response), five
genes that showed greater variation in their expression
(up or down regulation) were selected for detailed
analysis: IL-1-α, IL-18, BCL-2, EP-300, and PTGS-2. The
relative expression of IL-1-α (Fig. 3a) and IL-18 (Fig. 3b)
genes in HGF-1 decreased with 10 μg/mL or 20 μg/mL of
β-glucan in comparison with the control group (p < 0.05).
In the same way, the expression of PTGS-2 (Fig. 3e) de-
creased with 10 μg/mL treatment; however, at a dose of
20 μg/mL it remained equal to that of the control group
(p < 0.05). The expression of the BCL-2 (Fig. 3c) and EP-
300 (Fig. 3d) genes were similar among groups.
For OBA-9, the expression of the IL-1-α (Fig. 4a) gene
increased with 20 μg/mL and IL-18 (Fig. 4b) expression
increased with 10 μg/mL (p < 0.05). The expression of
BCL-2 (Fig. 4c), EP 300 (Fig. 4d), and PTGS-2 (Fig. 4e)
decreased with the higher dose of β-glucan (p < 0.05).
The metabolomic study yielded a total of 283 metabo-
lites, of which 120 were identified. Some metabolites
presented significantly altered concentrations (Fig. 5). The20 μg/mL β-glucan treatment presented lower (p < 0.05)
concentrations of 4-aminobutyric acid (Fig. 5a). It was also
observed that the β-glucan treatments used decreased
(p < 0.05) the concentrations of 2-deoxytetronic acid
NIST (Fig. 5b) and oxalic acid (Fig. 5e) at both concen-
tration used (10 μg/mL and 20 μg/mL). Acetophenone
NIST (Fig. 5c), benzoic acid (Fig. 5d) and pinitol
(Fig. 5f ) presented reduced (p < 0.05) concentrations
when treated with only 10 μg/mL of β-glucan. All treat-
ments were compared with the control group.Discussion
Human gingival fibroblasts represent the main cell type
that form the soft connective tissues of the periodon-
tium. These cells have a direct interaction with bacteria
and their products [36], and perform an essential role in
the production of cytokines involved during the inflam-
matory process [23]. The β-glucans present a capacity to
stimulate the production of proinflammatory cytokines,
thus modulating immune responses both specific and
non-specific. Here, the authors extend further on their
previous in vivo discovery [25] by showing the effects of
β-glucans on gene expression of inflammatory cytokines
and the metabolomic profile of mammalian cells.
Fig. 3 Relative expression of genes on HGF-1 cells (fibroblasts) by
quantitative PCR: (a) interleukin 1 alpha (IL-1-α); (b) interleukin 18
(IL-18); (c) B-cell lymphoma 2 (BCL-2); (d) adenovirus E1A-associated
300 kDa protein (EP 300); (e) prostaglandin-endoperoxide synthase
2 (PTGS-2). Dual-chamber model inoculated with A. actinomicetemcomitans
and treated with different doses of β-glucan. The control group has their
mean expressed equal to 1 and treated groups have their mean relative to
the control group. The results were expressed by mean followed standard
deviation; n=6 and P<0.05
Fig. 4 Relative expression of genes on OBA-9 cells (keratinocytes) by
quantitative PCR: (a) interleukin 1 alpha (IL-1-α); (b) interleukin 18
(IL-18); (c) B-cell lymphoma 2 (BCL-2); (d) adenovirus E1A-associated
300 kDa protein (EP 300); (e) prostaglandin-endoperoxide synthase 2
(PTGS-2). Dual-chamber model inoculated with A. actinomicetemcomitans
and treated with different doses of β-glucan. The control group has their
mean expressed equal to 1 and treated groups have their mean relative to
the control group. The results were expressed by mean followed standard
deviation; n=6 and P<0.05
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and effects on the transcriptome/metabolome of
β-glucans on human cells were evaluated. The gene ex-
pression of IL-1-α and IL-18 in fibroblasts was reduced
in the models treated with β-glucans. IL-1 is considered
as a marker of periodontitis due to their involvement in
the inflammation process (as inflammatory mediator)
and its participation in the extracellular matrix and bone
metabolism [37, 38]. In a study of experimental gingi-
vitis, an increased concentration of IL-1 in gingival cre-
vicular fluid was demonstrated [39]. The expression of
IL-1-α and IL-1-β was induced in vitro from cultured
gingival epithelial cells that were challenged with A. acti-
nomicetemcomitans extracts [40]. These results indicate
that gingival epithelial cells are the main source of these
interleukins of the periodontium, which induce the pro-
duction of additional inflammatory mediators [40]. IL-18
has pleiotropic action and participates in the innate andacquired immune responses [41], indicating a positive
effect of β-glucan in reducing the expression of both IL-
1-α and IL-18 in human fibroblasts. The decrease in
these parameters may suggest an improvement in the
inflammatory response associated with the immuno-
modulatory effects of β-glucans associated with their
antimicrobial activity [3, 42–44]. Antagonistically, the
expression of these same cytokines (IL-1-α and IL-18)
observed in keratinocytes (OBA-9), indicated a result
contrary to that seen in fibroblasts (HGF-1). Treatment
with β-glucan increased the expression of IL-1-α and
IL-18. This response may be due to a compensatory
interaction between these different cell types. According
to Di et al. [45], the expression of KGF (keratinocyte
growth factor) and KGFR (keratinocyte growth factor
receptor) observed in cocultures of keratinocytes and
fibroblasts was influenced by the interaction of these
different gingival cells. According to these authors, kera-
tinocytes and fibroblasts can interact to dynamically
Fig. 5 Metabolites obtained of cell culture supernatant (HGF-1 and OBA-9 co-culture cells). (a) 4-aminobutyric acid; (b) 2-deoxytetronic acid NIST;
(c) acetophenone NIST; (d) benzoic acid; (e) oxalic acid; (f) pinitol. Dual-chamber model inoculated with A. actinomicetemcomitans and treated
with different doses of β-glucan. The data is expressed in relative peak heights (mAU) from HPLC-MS analysis, which are unit-less (mean followed
standard deviation); n = 4 and P < 0.05
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fect on gingival cells conditions after treatment. In
addition, the use of β-glucan decreased BCL-2 expression
in keratinocytes. This protein exerts an antiapoptotic
function, performing an essential role in the development
of the immune response and tissue homeostasis [46].
β-glucan therapy regulated the expression of other im-
munomodulatory genes (EP300 and PTGS2), which
shows an effect on more than one signaling pathway and
can result in an important therapeutic effect. EP300, also
known as p300, is involved in cell growth, proliferation,
apoptosis, and embryogenesis [47, 48]. Some changes in
its structure (derived from mutations) and the altered
activity of this protein are linked with inflammation, ma-
lignant tumors, and developmental abnormalities [48].
Deng et al. [49] observed that p300 is involved in the
stimulation of COX-2 expression induced by proinflam-
matory mediators. In the current study, treatment with
β-glucan reduced EP300 expression in keratinocytes.
PTGS2, also known as COX-2, is an enzyme that is in-
volved in the conversion of arachidonic acid toprostaglandins, performing an important role in the in-
flammatory response of periodontal tissues [50]. This en-
zyme has a preferentially inducible profile and is
expressed by cells related to inflammatory processes [51]
such as the response to inoculation by pathogenic micro-
organisms. A recent study performed by our research
group demonstrated lower COX-2 expression in diabetic
rats with induced periodontal disease that were treated
with β-glucan from S. cerevisiae [25]. Similarly, the present
study showed a reduction in PTGS-2 expression, suggest-
ing an improvement in the inflammatory profile as a func-
tion of treatment with β-glucan.
The metabolomic study in the present work explored
the influence of β-glucan treatment on cell metabolic
profile and found significant changes in 4-aminobutyric
acid, 2-deoxytetronic acid NIST, oxalic acid, acetophe-
none NIST, benzoic acid, and pinitol. 4-aminobutyric
acid, more commonly known as gamma-aminobutyric
acid (GABA), is a non-protein amino acid that acts as
the main inhibitory neurotransmitter of the central ner-
vous system in animals and humans [52]. Some studies
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with multiple health benefits, for example, lowering
blood pressure in hypertensive animals and humans
[53–56]. In addition, studies indicate that GABA inges-
tion from enriched natural sources, has an inhibitory
effect on the proliferation of cancer cells and has a en-
hancer action on cancer cell apoptosis [57]. Other com-
pounds, such as benzoic acid and pinitol, are derived
from plants and have multifunctional properties. Ben-
zoic acid is an aromatic carboxylic acid present in the
tissues of plants and animals and can also be produced
by microorganisms [58]. Pinitol, also called D-pinitol, is
a compound with multifunctional properties, among
them, anti-inflammatory, cardioprotective, and anti-
hyperlipidemicactions. Furthermore, pinitol is known
to have properties similar to those of insulin [59–61].
A study compared the metabolomic profile of patients
with different levels of gingival bleeding. Metabolomic
analysis of this study indicated significant changes in the
composition of metabolites, especially the short chain
carboxylic acids propionate and n-butyrate, which
tracked clinical changes in gingivitis severity [62].
Another study analyzed the metabolomic profile in saliva
and plasma samples of diabetic patients with healthy
periodontium, gingivitis and periodontitis. They
observed increased levels of markers of cellular energetic
stress, increased purine degradation and glutathione me-
tabolism through increased levels of oxidized glutathione
and cysteine-glutathione disulfide, markers of oxidative
stress (guanosine and inosine), increased amino acid
levels suggesting protein degradation, and increased ω-3
(docosapentaenoate) and ω-6 fatty acid (linoleate and
arachidonate). According to the authors, these metabo-
lites associated with the periodontal condition may be
useful for developing diagnoses and therapeutics adapted
to the diabetic population [63]. Thus, we believe that
metabolomic profile analysis may be a useful tool in in-
vestigating of the β-glucans action on periodontal dis-
ease and the changes in metabolites can be used as
markers of the disease.
The results observed in the present study demon-
strated that the β-glucan was able to modulate gene ex-
pression and alter the concentrations of different
metabolites by modifying the immune cell response to a
challenge with A. actinomicetemcomitans. β-glucan
treatment (10 μg/mL or 20 μg/mL) reduced the concen-
trations of 4-aminobutyric acid, 2-deoxytetronic acid
NIST, oxalic acid, acetophenone NIST, benzoic acid, and
pinitol. In fibroblasts (HGF-1), the relative expression of IL-
1-α, IL-18, and PTGS-2 genes decreased with 10 μg/mL or
20 μg/mL of β-glucan. In keratinocytes (OBA-9), the ex-
pression of BCL-2, EP-300, and PTGS-2 decreased with the
higher dose of β-glucan. Such genes are considered a
marker for many dysfunctions, such as periodontal disease,due to their functions as inflammatory mediators. The
modulation of gene expression these markers may indicate
an improvement in inflammatory profile and a possible
reduction in microbial activity.
Conclusions
Treatment with β-glucans from Saccharomyces cerevi-
siae administered for 24 h in a dual-chamber model
positively modulated the immune response and metabo-
lites production.
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